Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Trial Profile

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Antiandrogens (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Zoledronic acid (Primary) ; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAMPEDE
  • Most Recent Events

    • 05 Nov 2018 Planned number of patients changed from 11200 to 12200.
    • 31 Aug 2018 Biomarkers information updated
    • 23 Mar 2018 Planned number of patients changed from 8100 to 11200.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top